Envisagenics

Envisagenics is a biotechnology company using artificial intelligence and RNA sequencing to discover and develop therapeutics that arrest RNA splicing errors in cancer and genetic diseases. The company is headquartered in New York City, New York and was founded in 2014 by Maria Luisa Pineda and Martin Akerman.

Funding

Seed round

On November 23, 2017 Envisgenics closed their seed funding round with $2.35 million in funding. Dynamk Capital lead the seed funding round, but several other investors participated, including: Third Kind Venture Capital, SV Angel, New York State, Dolby Family Ventures, and Cosine.

Timeline

April 22, 2014

Envisagenics was founded by Martin Akerman and Maria Luisa Pineda.

People

Name

Role

Adam Geier

Employee

Adrian Krainer

Professor & Program Chair

Anson Abraham

Employee

Derrick Stroman

Employee

Gillian Sandler

Investor

Maria Luisa Pineda

Founder

Maria Luisa Pineda

Co-Founder & CEO

Martin Akerman

Founder

Martin Akerman

Co-Founder & CTO

Michael Schatz

Associate Research Professor

Michael Zhang

Professor & Director

Omar Abdel-Wahab

Hematologic Oncologist

Tiffany Tsui

Employee

Documentaries, videos and podcasts

Title

Date

Link

+ Add new row

Companies

Company

CEO

Location

Products/Services

+ Add new row

Funding

Seed round

Timeline

Envisagenics was founded by Martin Akerman and Maria Luisa Pineda.

People

Further reading

Documentaries, videos and podcasts

Companies

References

Envisagenics

Company attributes

Categories

Related Topics

Contributors